Weiss, Glen J.
Jameson, Gayle
Von Hoff, Daniel D.
Valsasina, Barbara
Davite, Cristina
Di Giulio, Claudia
Fiorentini, Francesco
Alzani, Rachele
Carpinelli, Patrizia
Di Sanzo, Alessandro
Galvani, Arturo
Isacchi, Antonella
Ramanathan, Ramesh K.
Funding for this research was provided by:
Nerviano Medical Sciences S.r.l
Article History
Received: 2 June 2017
Accepted: 7 July 2017
First Online: 20 July 2017
Compliance with ethical standards
:
: Glen Weiss has no direct conflicts of interest related to this work, but has the following unrelated disclosures: consulting or advisory roles with Pharmatech, Paradigm, Blend Therapeutics, and Viomics; service on speakers’ bureaus with Medscape, Novartis, and Merck; and receipt of travel and accommodation expenses from Nantworks. Rachele Alzani, Patrizia Carpinelli, Arturo Galvani, Antonella Isacchi, and Barbara Valsasina are employees of Nerviano Sciences s.r.l. Francesco Fiorentini is an employee of Accelera s.r.l. Cristina Davite, Claudia Di Giulio, and Alessandro Di Salvo are employees of Clioss s.r.l. Gayle Jameson, Daniel Von Hoff, and Ramesh Ramanathan have no conflicts to disclose.
: The study protocol, amendments to the protocol, and the sample informed consent file were reviewed and approved by the Institutional Review Board (IRB) at the study site. The study conformed to Good Clinical Practice guidelines published by the International Council for Harmonization (ICH), ethical principles as set forth in the Declaration of Helsinki (1996 version), and all applicable local regulatory requirements and laws.
: Signed written informed consent was obtained from each patient prior to undertaking any trial-related procedure.
: This study was funded by Nerviano Medical Sciences S.r.l, Nerviano, Italy.